Additionally, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), liver hepatocellular carcinoma (LIHC), brain lower grade glioma (LGG) and adrenocortical carcinoma (ACC) patients acquiring high expression of TEx signature genes also had a decreased OS and DFS as compared to those of tumor patients acquiring low expression of these signature genes (Supplementary Fig. 6). This evidence concerns the gene TEX46 and adrenal cortex carcinoma.